Aclaris Therapeutics Q1 EPS $(0.24) Beats $(0.29) Estimate, Sales $2.40M Beat $1.37M Estimate

Author: Benzinga Newsdesk | May 07, 2024 04:02pm
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 42.86 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $1.37 million by 75.04 percent. This is a 5.14 percent decrease over sales of $2.53 million the same period last year.

Posted In: ACRS